Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 438 for “"BRAF"”.
-
MECHANISTIC INVESTIGATIONS OF A NOVEL BRAF REGULATORY SWITCH AND BRAFTIDE, AN ALLOSTERIC PEPTIDE INHIBITOR OF BRAF
RAF kinases (ARAF/BRAF/CRAF or Raf-1) are serine/threonine kinases in the MAPK (RAS-RAF-MEK-ERK) pathway. The MAPK pathway is crucial in development and normal cell function. These same roles are dysregulated in cancer; BRAF is the most frequently mutated isoform in cancers and in particular, …
-
New insights into the KIAA1549::BRAF fusion protein and the regulation of BRAF phosphorylation at threonine 401
… is primarily driven by a fusion of the oncogene BRAF with the relatively uncharacterised protein KIAA1549. The fusion gene results from a tandem duplication event that combines the 5' region of KIAA1549 with the 3' region of BRAF. BRAF is a well-characterised protein, that plays a pivotal role in …
-
Post-translational modifications of BRAF and MITF
… driving melanoma tumorigenesis. We showed that BRAF, the most commonly mutated oncoprotein in melanoma, can be acetylated at K473 and K475 by the p300/CBP acetyltransferases. Importantly, acetylation of BRAF reduced its activity regardless of its mutational status at the commonly mutated V600 …
-
Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer
Introduction: BRAF V600E mutations are associated with poor clinical outcomes for patients with metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are associated with global …
-
New therapeutic concepts for BRAF-driven colorectal cancer
The kinase-activating BRAFV600E mutation occurs in about 10 % of colorectal cancer (CRC) patients and confers a poor prognosis. In order to evaluate novel treatment approaches such as the combination of immunotherapy with kinase inhibition, syngeneic preclinical models are urgently needed, but …
-
Establishing the 6-month resource utilization and cost-of-care for the treatment of first-line metastatic BRAF (+) melanoma with combination BRAF & MEK inhibitors
… helpful as value-based healthcare moves forward. BRAF & MEK inhibitor combinations are considered first-line treatment for BRAF (V-600) metastatic melanoma (MM), although head-to-head trials are lacking. We aimed to establish the real-world HCRU and 6-month cost-of-care in V-600 MM treated with …
-
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
… selective pressure to engage any of the many BRAF-independent ERK1/2 pathway activation mechanisms. By integration of multi-genome chemical and genetic screens; recurrent architectural variants in melanoma tumor genomes; and patient outcome data; we identified 2 mechanistic subtypes of …
-
Oncogenic GNAQ and BRAF in epidermal versus non-epidermal melanocytes
… epidermis or conjunctiva of the eye, activating BRAF mutations are frequently found. In contrast, activating GNAQ/11 mutations are virtually absent in those lesions, and instead are frequently found in lesions located in non-epithelial sites, such as the skin dermis, uveal tract of the eye, or …
-
Roles For Braf Kinase Activating Mutations In Melanoma: Microenvironmental Immunosuppression
<p>The BRAF oncogene demonstrates a characteristic mutation (V600E) in a significant fraction of cutaneous melanomas, leading to constitutive activation of the MAP kinase pathway. This genetic lesion endows tumor cells with proliferative and survival advantages, and metastatic melanoma patients …
-
Pre-clinical modelling and treatment of Braf mutant colorectal cancer
Abstract not currently available.
-
Autocrine and paracrine effects of BRAF inhibitor induced senescence in melanoma
The FDA approval of targeted therapy with BRAFV600E inhibitors like vemurafenib and dabrafenib in 2011 has been the first major breakthrough in the treatment of metastatic melanoma since almost three decades. Despite increased progression free survival and elevated overall survival rates, complete …
Page 1 of 22